478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. (23rd October 2018)

Record Type:: Journal Article
Title:: 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. (23rd October 2018)
Main Title:: 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?
Authors:: Mata Velasco, E
González-Flores, E
Juez Martel, I
Alonso, V
Iranzo Gomez, P
Martinez Lago, N
Lopez, C
Cabrera Romero, J M
Safont Aguilera, M J
Ruiz Casado, A
Salgado Fernandez, M
González Astorga, B
Escudero, P
Rivera Herrero, F
Pericay Pijaume, C
Vera, R
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 8
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Issue Display:: Volume 29, Issue 8 (2018)
Year:: 2018
Volume:: 29
Issue:: 8
Issue Sort Value:: 2018-0029-0008-0000
Page Start:
Page End:
Publication Date:: 2018-10-23
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy281.026 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12254.xml